R&D /Discovery

Design and efficacy of a monovalent bispecific PD-1/CTLA-4 antibody that enhances CTLA-4 blockade on PD-1+ activated T cells

Details

Published:

Cancer Discovery

AstraZeneca author(s):

Related Content:
Dual-action-to-improve-target-specificity

Dual action to improve target specificity